People · Operator
Named in public records as an officer, director or promoter · active 2015–2023 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Genesis Therapeutics, Inc. | — | Biotechnology | Series D+ | $297.4M | $3.3B | 2020 |
| Avenida Inc. | — | Other Technology | Series B | $30.0M | $913.7M | 2015 |
EVAN FEINBERG at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside EVAN FEINBERG on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Vijay Pande | 1 | 9 |
| William McCarthy | 1 | 4 |
| Daniel Green | 1 | 3 |
| Stephen Dann | 1 | 2 |
| BENJAMIN SKLAROFF | 1 | 1 |
| NICHOLAS STOCK | 1 | 1 |
| Cristina Berta | 1 | 1 |
| Santiago Bilinkis | 1 | 1 |
| Gaston Lernoud | 1 | 1 |
| Federico Malek | 1 | 1 |
| PEPTIBOON PRASIT | 1 | 1 |
| LEONARD BELL | 1 | 1 |
| KRIS JENNER | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.